Announcement
12 May 2025
In May 2025, the US Administration issued an Executive Order directing federal agencies to ensure that American patients pay no more than the lowest price charged for prescription drugs in other developed nations.
Source
Number of interventions
1
0 certainly harmful
1 likely harmful
0 liberalising
Implementation date
No implementation date
Revocation date:
No revocation date
23 Apr 2026
United States of America: Agreement with Regeneron on Most-Favoured-Nation drug pricing and tariff exemption
12 Jan 2026
United States of America: Agreement with AbbVie on Most-Favoured-Nation drug pricing and tariff exemption
08 Jan 2026
United States of America: Agreement with Johnson & Johnson on Most-Favoured-Nation drug pricing and tariff exemption
19 Dec 2025
United States of America: Agreement with Gilead on Most-Favoured-Nation drug pricing and tariff exemption
19 Dec 2025
United States of America: Agreement with GSK on Most-Favoured-Nation drug pricing and tariff exemption
19 Dec 2025
United States of America: Agreement with Merck on Most-Favoured-Nation drug pricing and tariff exemption
19 Dec 2025
United States of America: Agreement with Novartis on Most-Favoured-Nation drug pricing and tariff exemption
19 Dec 2025
United States of America: Agreement with Sanofi on Most-Favoured-Nation drug pricing and tariff exemption
19 Dec 2025
United States of America: Agreement with Amgen on Most-Favoured-Nation drug pricing and tariff exemption
19 Dec 2025
United States of America: Agreement with Boehringer Ingelheim on Most-Favoured-Nation drug pricing and tariff exemption
19 Dec 2025
United States of America: Agreement with Bristol Myers Squibb on Most-Favoured-Nation drug pricing and tariff exemption
19 Dec 2025
United States of America: Agreement with Genentech on Most-Favoured-Nation drug pricing and tariff exemption
01 Apr 2025
United States of America: U.S. Administration imposes Section 232 tariffs on pharmaceutical imports
See all
This state act is not part of any Thread yet.